PTC THERAPEUTICS INC (PTCT) Stock Analyst Ratings
NASDAQ:PTCT • US69366J2006
70.66 USD
+0.76 (+1.09%)
At close: Feb 20, 2026
70.66 USD
0 (0%)
After Hours: 2/20/2026, 8:00:20 PM
ChartMill assigns a Buy % Consensus number of 79% to PTCT. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 89.01. This target is 25.97% above the current price.
- PTCT was analyzed by 22 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about PTCT.
- In the previous month the buy percentage consensus was at a similar level.
- PTCT was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-20 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-20 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-28 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2025-12-01 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-11-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-05 | TD Cowen | Maintains | Hold -> Hold |
| 2025-11-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-11-05 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-28 | Jefferies | Maintains | Buy -> Buy |
| 2025-09-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-07-29 | UBS | Maintains | Buy -> Buy |
| 2025-07-29 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-29 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-28 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-06-17 | Truist Securities | Initiate | Buy |
| 2025-05-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-09 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-05-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
PTC THERAPEUTICS INC / PTCT FAQ
What is the average price target for PTC THERAPEUTICS INC (PTCT) stock?
22 analysts have analysed PTCT and the average price target is 89.01 USD. This implies a price increase of 25.97% is expected in the next year compared to the current price of 70.66.
What is the consensus rating for PTCT stock?
The consensus rating for PTC THERAPEUTICS INC (PTCT) is 79.0909 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover PTC THERAPEUTICS INC (PTCT) stock?
The number of analysts covering PTC THERAPEUTICS INC (PTCT) is 22.